
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Scilex Holding Company

(Name of Issuer)

Common Stock par value \$0.0001 per share

(Title of Class of Securities)

80880W106

(CUSIP Number)

01/13/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)
-
-

SCHEDULE 13G

CUSIP No. 80880W106

Names of Reporting Persons

1

Oramed Pharmaceuticals Inc.

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Number of Shares 5 Sole Voting Power

Beneficially 15,500,000.00
Owned by Shared Voting Power
Each 6
Reporting 0.00
Person
With: Sole Dispositive Power
7
15,500,000.00
Shared Dispositive
8 Power
0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

15,500,000.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Percent of class represented by amount in row (9)

6.2 %

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: Note to Rows 5, 7, 9: Comprised of (i) 9,000,000 shares of common stock, par value \$0.0001 per share ("Common Stock"), of Scilex Holding Company (the "Issuer"), and (ii) 6,500,000 shares of Common Stock issuable upon exercise of warrants exercisable within 60 days of the date on which this Schedule 13G has been filed with the Securities and Exchange Commission ("SEC"). Note to Row 11: Percent of class beneficially owned is calculated based on 243,312,885 shares of Common Stock outstanding as of January 6, 2025 as represented by the Issuer, plus 6,500,000 shares of Common Stock issuable upon exercise of warrants held by the Reporting Person that are exercisable within 60 days of the date on which this Schedule 13G has been filed with the SEC.

SCHEDULE 13G

Item 1.

Name of issuer:

(a)

Scilex Holding Company

Address of issuer's principal executive offices:

(b)

960 San Antonio Road, Palo Alto, California, 94303

Item 2.

Name of person filing:

(a)

Oramed Pharmaceuticals Inc. ("Oramed")

Address or principal business office or, if none, residence:

(b)

1185 Avenue of the Americas, Third Floor, New York, NY 10036

Citizenship:

(c)

Delaware

Title of class of securities:

(d)

Common Stock par value \$0.0001 per share

CUSIP No.:

(e)

80880W106

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
- (j) Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

- (a) The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The amount beneficially owned is comprised of (i) 9,000,000 shares of common stock, par value \$0.0001 per share ("Common Stock"), of Scilex Holding Company (the "Issuer"), and (ii) 6,500,000 shares of Common Stock issuable upon exercise of warrants exercisable within 60 days of the date on which this Schedule 13G has been filed with the Securities and Exchange Commission ("SEC").

Percent of class:

- (b) The information required by Item 4(b) is set forth in Row 11 of the cover page for the Reporting Person and is incorporated herein by reference. The percent of class beneficially owned reported in Row 9 of the cover page for the Reporting Person is calculated based on 243,312,885 shares of Common Stock outstanding as of January 6, 2025 as represented by the Issuer, plus 6,500,000 shares of Common Stock issuable upon exercise of warrants held by the Reporting Person that are exercisable within 60 days of the date on which this Schedule 13G has been filed with the SEC. This calculation results in 6.2 %

- (c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

15,500,000

(ii) Shared power to vote or to direct the vote:

0

(iii) Sole power to dispose or to direct the disposition of:

15,500,000

(iv) Shared power to dispose or to direct the disposition of:

0

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of

the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Oramed Pharmaceuticals Inc.

Signature: /s/ Avraham Gabay

Name/Title: Avraham Gabay/Chief Financial Officer

Date: 01/17/2025